Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGHUMSC001 umbilical cord mesenchymal stem cell injection in knee osteoarthritis (Phase II)
CTR20240818Phase 2Active
- Sponsor
- Guizhou Zhongguan Biotechnology
- Start
- Nov 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ZGHUMSC001 in knee osteoarthritis (OA) (4 arms), sponsored by Guizhou Zhongguan Biotechnology. Primary endpoint: Change from baseline in total WOMAC score at Week 52. Started Nov 2024; status: active.
02
Drugs
ZGHUMSC001
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on CTR20240818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240818.